Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
The Oncologist|April 17, 2024
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimensEddy Saad, Georges Gebrael, Karl Semaan, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
Cancer Cell|January 16, 2026
A context-augmented large language model for accurate precision oncology medicine recommendationsHyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
European Urology Focus|December 8, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell CarcinomaJustine Panian, Caiwei Zhong, Sharon H Choi, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancerSabrina Y Camp, Meng Xiao He, Michael S Cuoco, et al.
Nature Medicine|January 7, 2026
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinomaCarolina Alves Costa Silva, Marc Machaalani, Renee Maria Saliby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate CancerDavid D Yang, Aya Abdelnaser, Alexander J Haas, et al.
JCO Oncology Practice|October 7, 2024
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of PracticeNazli Dizman, Ziad Bakouny, Tarek Haykal, et al.
Cancer Cell|April 5, 2024
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomesRenée Maria Saliby, Chris Labaki, Tejas R Jammihal, et al.
JAMA Network Open|April 15, 2026
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell CarcinomaMartin Zarba, Eddy Saad, Karl Semaan, et al.
Pageof 5